CURA Share Price Performance
CA$2.77
1.34 (93.71%)
43.5% undervalued intrinsic discount
CA$4.90
Fair Value
Price CA$2.77
AnalystConsensusTarget CA$4.90
AnalystHighTarget CA$5.50
AnalystLowTarget CA$4.37
Fair ValueCA$4.90
Share Pricen/a
Curaleaf Holdings, Inc. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 29 Fair Values set on narratives written by author
CURA Community Narratives
AN
Fair Value CA$4.9 43.5% undervalued intrinsic discount
Regulatory Winds Will Drive New Industry Leadership And Outperformance Opportunities
1users have liked this narrative
0users have commented on this narrative
16users have followed this narrative
AN
Fair Value CA$5.5 49.6% undervalued intrinsic discount
Medical Cannabis Legalization And Wellness Trends Will Redefine Market Opportunities
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value CA$4.37 36.6% undervalued intrinsic discount
Intensified Global Regulation Will Squeeze Cannabis Margins Despite European Hopes
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Regulatory Winds Will Drive New Industry Leadership And Outperformance Opportunities
Key Takeaways International market growth, product innovation, and strategic R&D investments are set to diversify revenue streams and strengthen long-term growth prospects. Vertical integration, supply chain optimization, and industry consolidation are expected to boost margins, market share, and operational efficiency.Read more
401
users have viewed this narrative1users have liked this narrative
0users have commented on this narrative
16users have followed this narrative
AN
CA$4.9
43.5% undervalued intrinsic discount
Fair Value
Profit Margin
5.64%
Future PE
40.59x
Price in 2029
CA$5.9
Medical Cannabis Legalization And Wellness Trends Will Redefine Market Opportunities
Key Takeaways International expansion, innovation in medical devices, and proprietary brands position Curaleaf for significant gains in revenue, margin, and category leadership as global markets open. Operational efficiency, premium product offerings, and asset-light strategies underpin resilience, recurring growth, and outsized market share amid broad industry legalization and normalization.Read more
24
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
CA$5.5
49.6% undervalued intrinsic discount
Fair Value
Profit Margin
5.92%
Future PE
43.14x
Price in 2029
CA$6.63
Intensified Global Regulation Will Squeeze Cannabis Margins Despite European Hopes
Key Takeaways Intensifying regulatory scrutiny, price compression, and new competitors threaten margins, market share, and long-term profitability. Heavy investment and macroeconomic headwinds risk ongoing negative cash flow and shrinking shareholder value.Read more
20
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
CA$4.37
36.6% undervalued intrinsic discount
Fair Value
Profit Margin
5.77%
Future PE
35.42x
Price in 2029
CA$5.26
Trending Discussion
Recently Updated Narratives
AN
CURA: Domestic Stabilization And International Expansion Will Support Wider Future Moat
Fair Value: CA$4.9 43.5% undervalued intrinsic discount
16 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
CURA: Domestic Stabilization And International Expansion Will Support Future Upside
Fair Value: CA$5.5 49.6% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
CURA: Expanded Retail Footprint And Higher Guidance Will Support Bullish Re Rating
Fair Value: CA$4.37 36.6% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Curaleaf Holdings, Inc. Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
n/a
- -0.32
- 49.76%
- -19.49%
- 90.3%
About CURA
- Founded
- n/a
- Employees
- 5554
- CEO
- WebsiteView website
Curaleaf Holdings, Inc. engages in the retail and wholesale of cannabis products in the United States and internationally. The company operates licensed cultivation; and pharma-grade cannabis processing and manufacturing facilities. It also supplies cannabis on a wholesale basis to Australia, New Zealand, the United Kingdom and various European countries, including Germany, Italy, Poland, the Czech Republic, Switzerland, Sweden and Norway. In addition, the company operates a medical cannabis clinic and holds a pharmacy license. It serves the medical and adult-use cannabis markets through retail and wholesale channels. The company is based in Stamford, Connecticut.
